Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12635916 | 1.00 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL8254461 | 1.00 | ARG1 (0.33) | ARG1ARG2 | |
| SCHEMBL13385283 | 0.85 | — | — | |
| SCHEMBL13127843 | 0.84 | — | — | |
| SCHEMBL12914843 | 0.84 | — | — | |
| SCHEMBL6760012 | 0.84 | THRB (0.33) | — | |
| SCHEMBL1101939 | 0.84 | — | — | |
| SCHEMBL15653894 | 0.82 | KDM4E (0.32) | — | |
| SCHEMBL31716111 | 0.81 | — | — | |
| SCHEMBL31717005 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9023808-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2015-05-05 | — | — | US | disclosed |
| US-8383584-B2 | HCV inhibiting macrocyclic phenylcarbamates | MEDIVIR AB (SE) | 2013-02-26 | — | — | US | disclosed |
| US-8227407-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2012-07-24 | — | — | US | disclosed |
| US-8183277-B2 | Inhibitors of HCV replication of formula (I)** Image-1whereinW is a heterocycle of formula** Image-2and the remaining variables are as defined in the specification. | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-05-22 | — | — | US | disclosed |
| US-8148399-B2 | Macrocyclic inhibitors of hepatitis C virus | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2012-04-03 | — | — | US | disclosed |
| US-8012939-B2 | Macrocyclic inhibitors of hepatitis C virus | Tibotec Pharmaceuticals Ltd. Co (IE) | 2011-09-06 | — | — | US | disclosed |
| US-8008251-B2 | Bioavailable formulations with ritonavir; potency, decreased cytotoxicity, improved pharmacokinetics; N-[18-[2-(4-isopropylthiazol-2-yl)-7-methoxyquinolin-4-yl-oxy]-2,15-dioxo- -3,14,16-triazatricyclo[14.3.0.0.sup.4,6]nonadec-7-ene-4-carbonyl]-(cyclopropyl)sulfonamide | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2011-08-30 | — | — | US | disclosed |
| EP-2322516-A1 | Intermediates for the preparation of Macrocyclic inhibitors of hepatitis c virus | Tibotec Pharmaceuticals Ltd. (IE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100173939-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-03-05 | — | — | US | disclosed |
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | MEDIVIR AB (SE) | 2009-01-22 | — | — | US | disclosed |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-10-23 | — | — | US | disclosed |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2008-08-21 | — | — | US | disclosed |
| WO-2008096001-A1 | HCV INHIBITING MACROCYCLIC PHENYLCARBAMATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008096002-A1 | HCV INHIBITING MACROCYCLIC PHOSPHONATES AND AMIDOPHOSPHATES | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-08-14 | — | — | WO | disclosed |
| WO-2008059046-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2008-05-22 | — | — | WO | disclosed |
| WO-2007014919-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2007-02-08 | — | — | WO | disclosed |
| EP-1615949-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC COMPOUNDS BY RUTHENIUM COMPLEX CATALYSED METATHESIS REACTION | Boehringer Ingelheim International GmbH (DE) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004089974-A1 | PROCESS FOR THE PREPARATION OF MACROCYCLIC COMPOUNDS BY RUTHENIUM COMPLEX CATALYSED METATHESIS REACTION | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023758-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | CTRC, NOX3, HAVCR2 | ARG1 652/4885ARG2 2581/4885 |
| US-20100173939-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, ZC3HAV1, EIF2AK2 | ARG1 1137/4885ARG2 1358/4885 |
| US-20080262058-A1 | Macrocylic Inhibitors of Hepatitis C Virus | HAVCR2, HCCS, EIF2AK2 | ARG1 598/4885ARG2 1183/4885 |
| US-20080200503-A1 | Macrocylic Inhibitors Of Hepatitis C Virus | HAVCR2, HCCS, CYP7A1 | ARG1 112/4885ARG2 446/4885 |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | NR4A1, NR4A3, NR4A2 | ARG1 2027/4885ARG2 2735/4885 |
| US-20090062311-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | HCCS, NR5A1, NR0B1 | ARG1 879/4885ARG2 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.